Corbus Pharmaceuticals Holdings, Inc. Stock
Equities
CRBP
US21833P3010
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45 USD | -2.00% | +4.68% | +645.03% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 3.33M | Capitalization | 473M |
---|---|---|---|---|---|
Net income 2024 * | -49M | Net income 2025 * | -69M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 142 x |
P/E ratio 2024 * |
-7.68
x | P/E ratio 2025 * |
-7.75
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.32% |
Latest transcript on Corbus Pharmaceuticals Holdings, Inc.
1 day | -2.00% | ||
1 week | +4.68% | ||
Current month | +21.49% | ||
1 month | +23.19% | ||
3 months | +94.81% | ||
6 months | +876.14% | ||
Current year | +645.03% |
Managers | Title | Age | Since |
---|---|---|---|
Yuval Cohen
CEO | Chief Executive Officer | 49 | 13-06-30 |
Sean Moran
DFI | Director of Finance/CFO | 66 | 14-04-10 |
Chief Tech/Sci/R&D Officer | 50 | Feb. 27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Holmer
CHM | Chairman | 74 | 13-12-31 |
Avery Catlin
BRD | Director/Board Member | 75 | 14-07-31 |
Yuval Cohen
CEO | Chief Executive Officer | 49 | 13-06-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 45 | -2.00% | 123,942 |
24-05-16 | 45.92 | +4.03% | 124,277 |
24-05-15 | 44.14 | +2.68% | 251,856 |
24-05-14 | 42.99 | +0.28% | 106,446 |
24-05-13 | 42.87 | -0.28% | 151,982 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+645.03% | 473M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- CRBP Stock